Technical Analysis for RGLS - Regulus Therapeutics Inc.

Grade Last Price % Change Price Change
grade F 0.641 -0.62% 0.00
RGLS closed down 0.62 percent on Monday, October 14, 2019, on 15 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical RGLS trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Hammer Candlestick Bullish -0.62%
Lizard Bullish Bullish Day Trade Setup -0.62%
Wide Bands Range Expansion -0.62%
Oversold Stochastic Weakness -0.62%
Fell Below 50 DMA Bearish -0.42%

Older signals for RGLS ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat various diseases in the United States. The company utilizes its microRNA product platform to develop anti-miRs, a chemically modified single-stranded oligonucleotides. Its microRNA development candidates target miR-122 in hepatitis C virus infection; miR-21 and miR-221 in hepatocellular carcinoma; miR-21 in kidney fibrosis; miR-33 in atherosclerosis; and miR-10b in glioblastoma. The company has strategic alliances with AstraZeneca AB, GlaxoSmithKline plc, Sanofi, and Alnylam and Isis, as well as a strategic collaboration with Biogen Idec MA Inc. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
Biopharmaceutical Diseases Genetics Glioblastoma Regulus Therapeutics Hepatocellular Carcinoma RNA Alnylam Pharmaceuticals Hepatitis C Virus Infection Nucleic Acids Atherosclerosis Microrna
Is RGLS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 3.14
52 Week Low 0.5026
Average Volume 110,310
200-Day Moving Average 0.998
50-Day Moving Average 0.6671
20-Day Moving Average 0.7197
10-Day Moving Average 0.6648
Average True Range 0.0568
ADX 31.04
+DI 8.8139
-DI 23.0043
Chandelier Exit (Long, 3 ATRs ) 0.6896
Chandelier Exit (Short, 3 ATRs ) 0.7736
Upper Bollinger Band 0.8544
Lower Bollinger Band 0.585
Percent B (%b) 0.21
BandWidth 37.432263
MACD Line -0.0219
MACD Signal Line -0.0116
MACD Histogram -0.0103
Fundamentals Value
Market Cap 66.52 Million
Num Shares 104 Million
EPS -1.53
Price-to-Earnings (P/E) Ratio -0.42
Price-to-Sales 450.54
Price-to-Book 2.98
PEG Ratio -0.03
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.66
Resistance 3 (R3) 0.66 0.66 0.66
Resistance 2 (R2) 0.66 0.65 0.66 0.66
Resistance 1 (R1) 0.65 0.65 0.65 0.65 0.66
Pivot Point 0.64 0.64 0.64 0.64 0.64
Support 1 (S1) 0.63 0.64 0.63 0.63 0.62
Support 2 (S2) 0.63 0.63 0.63 0.62
Support 3 (S3) 0.62 0.63 0.62
Support 4 (S4) 0.62